The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The industry rank for TMC Life Sciences Bhd's 9-Day RSI or its related term are showing as below:
XKLS:0101's 9-Day RSI is ranked worse than 81.38% of 698
companies
in the Healthcare Providers & Services industry
Industry Median: 50.38
vs XKLS:0101: 70.66
TMC Life Sciences Bhd (XKLS:0101) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
TMC Life Sciences Bhd 9-Day RSI Related Terms
XKLS:0101 vs HCA, THC, DVA: 9-Day RSI Comparison
For the Medical Care Facilities subindustry, TMC Life Sciences Bhd's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TMC Life Sciences Bhd 9-Day RSI vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, TMC Life Sciences Bhd's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where TMC Life Sciences Bhd's 9-Day RSI falls into.
TMC Life Sciences Bhd (XKLS:0101) 9-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TMC Life Sciences Bhd (XKLS:0101) has a 9-Day RSI of 70.66 as of Jul. 12, 2026. According to the industry distribution chart, TMC Life Sciences Bhd ranks #568 out of 698 companies in the Healthcare Providers & Services industry, placing it in the top 81.4%.
Is TMC Life Sciences Bhd's 9-Day RSI too high?
TMC Life Sciences Bhd's current 9-Day RSI is 70.66. The Healthcare Providers & Services industry median 9-Day RSI is 50.38. TMC Life Sciences Bhd's value of 70.66 is 40.3% above this industry median. Based on the distribution chart, TMC Life Sciences Bhd ranks #568 out of 698 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, TMC Life Sciences Bhd has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TMC Life Sciences Bhd's 9-Day RSI compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, TMC Life Sciences Bhd ranks #568 out of 698 companies for 9-Day RSI. This places TMC Life Sciences Bhd in the lower half of its industry. The industry median 9-Day RSI is 50.38. TMC Life Sciences Bhd's value of 70.66 is 40.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Healthcare Providers & Services company?
The median 9-Day RSI among Healthcare Providers & Services companies is 50.38, based on 698 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TMC Life Sciences Bhd's current 9-Day RSI of 70.66 is 40.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median 9-Day RSI is 50.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TMC Life Sciences Bhd's current 9-Day RSI is 70.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TMC Life Sciences Bhd stock overvalued right now?
Based on GuruFocus' analysis, TMC Life Sciences Bhd (XKLS:0101) is currently considered Modestly Undervalued. The stock's GF Value™ is RM0.62, compared to a current price of RM0.47 — trading 25% below its estimated fair value. The current 9-Day RSI is 70.66 and 40.3% above the Healthcare Providers & Services industry median of 50.38. TMC Life Sciences Bhd's overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For TMC Life Sciences Bhd (XKLS:0101), the current 9-Day RSI is 70.66 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TMC Life Sciences Bhd (XKLS:0101) Overvalued in 2026?
Based on GuruFocus' analysis, TMC Life Sciences Bhd stock appears to be undervalued.
The current stock price of RM0.47 is trading 25% below its estimated GF Value™ of RM0.62.
GuruFocus considers TMC Life Sciences Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:0101:
9-Day RSI: 70.66
GF Value™: RM0.62 vs. price of RM0.47 (25% below fair value)
Industry Position: 40.3% above the Healthcare Providers & Services median (#568 of 698)
No single metric tells the full story. See the XKLS:0101 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TMC Life Sciences Bhd is an investment holding company operating a multi-disciplinary tertiary care center and fertility center in Malaysia. It operates Tropicana Medical Centre, Kota Damansara (TMCKD), a medical center located in Petaling Jaya. Its TMCKD provides healthcare services in various medical/surgical specialties and subspecialties, including anesthesiology, cancer, cardiology, colorectal, dermatology, ENT, fertility, gastroenterology, as well as offers internal medicines and respiratory medicines. Its fertility center provides a range of fertility treatments for couples. The company also operates a women's clinic; provides fertility consultancy, laboratory, and embryology services; and offers pharmacy services and products.
60GF Score
Get the complete analysis for XKLS:0101
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0101 has been successfully added to your 